Atrium Health Union
- Type
- Teaching hospital
- Where
- Monroe, NC
- Medicare CCN
- 340130
- Received
- $6,923,443 in 467 records, 2024 ($532,891 general, $6,390,551 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 21 | $532,891 |
| 2024 | Research payment | 446 | $6,390,551 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 446 | $6,390,551 |
| Grant | 8 | $403,337 |
| Education | 2 | $55,000 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 3 | $29,850 |
| Royalty or License | 1 | $26,567 |
| Debt forgiveness | 3 | $9,898 |
| Space rental or facility fees (teaching hospital only) | 3 | $7,239 |
| Consulting Fee | 1 | $1,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Merck Sharp & Dohme LLC | $2,375 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | STUDY NAME#The POUR Study# Effects of Neuromuscular Reversal Agents on Postoperative Urinary Retention POUR Following La | 2024 |
| 2024-12-23 | Gilead Sciences, Inc. | $40,209 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-23 | Janssen Research & Development, LLC | $1,403 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2024 |
| 2024-12-20 | Janssen Research & Development, LLC | $32,848 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-12-19 | Janssen Research & Development, LLC | $26,856 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2024 | |
| 2024-12-19 | ABBVIE INC. | $461 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2024 |
| 2024-12-19 | ABBVIE INC. | $461 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2024 |
| 2024-12-16 | Janssen Research & Development, LLC | $23,427 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-12-16 | Edwards Lifesciences Corporation | $16,030 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2024 | |
| 2024-12-13 | CSL Behring | $6,000 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-12-13 | CSL Behring | $5,500 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-12-13 | Janssen Research & Development, LLC | $4,480 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2024 |
| 2024-12-13 | Janssen Research & Development, LLC | $3,911 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2024 | |
| 2024-12-13 | Janssen Research & Development, LLC | $3,901 | Research payment | Cash or cash equivalent | A Multi arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2024 | |
| 2024-12-13 | Janssen Research & Development, LLC | $2,362 | Research payment | Cash or cash equivalent | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-I | 2024 | |
| 2024-12-13 | Janssen Research & Development, LLC | $1,064 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2024 | |
| 2024-12-13 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-12-13 | CSL Behring | $500 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-12-12 | Edwards Lifesciences Corporation | $12,521 | Research payment | Cash or cash equivalent | ALLIANCE AVIV 2021-05 | 2024 | |
| 2024-12-12 | Edwards Lifesciences Corporation | $5,091 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2024 | |
| 2024-12-06 | Janssen Research & Development, LLC | $12,795 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2024 |
| 2024-12-05 | Genmab U.S., Inc. | $518 | Research payment | Cash or cash equivalent | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With | 2024 | |
| 2024-12-05 | Genmab U.S., Inc. | $518 | Research payment | Cash or cash equivalent | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With | 2024 | |
| 2024-12-05 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Rivacor 7 DR-T Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Rivacor 7 DR-T Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Rivacor 7 DR-T Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $160 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-05 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-12-02 | PFIZER INC. | $506 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT | 2024 |
| 2024-11-27 | CSL Behring | $8,000 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-11-27 | CSL Behring | $5,200 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-11-27 | CSL Behring | $4,500 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-11-23 | Edwards Lifesciences Corporation | $9,959 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2024 | |
| 2024-11-22 | Merck Sharp & Dohme LLC | $694 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2024 |
| 2024-11-21 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-11-18 | CSL Behring | $135,411 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-11-13 | CSL Behring | $42,331 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-11-12 | Janssen Research & Development, LLC | $23,916 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-11-08 | Janssen Research & Development, LLC | $41,611 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2024 |
| 2024-11-04 | Janssen Research & Development, LLC | $932 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk | 2024 |
| 2024-11-03 | Medical Device Business Services, Inc. | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-11-01 | Janssen Research & Development, LLC | $11,751 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-11-01 | Janssen Research & Development, LLC | $2,498 | Research payment | Cash or cash equivalent | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-I | 2024 | |
| 2024-10-28 | Janssen Research & Development, LLC | $1,300 | Research payment | Cash or cash equivalent | A Multi arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2024 | |
| 2024-10-25 | Janssen Research & Development, LLC | $3,548 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2024 | |
| 2024-10-25 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-10-24 | Silk Road Medical, Inc. | $1,210 | Research payment | Cash or cash equivalent | ENROUTE Transcarotid Stent Device, Cardiology/Vascular Diseases | Roadster 3 | 2024 |
| 2024-10-24 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-10-23 | GLOBAL BLOOD THERAPEUTICS, INC. | $3,893 | Research payment | Cash or cash equivalent | OXBRYTA Drug, HEMATOLOGY | AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXEL | 2024 |
| 2024-10-21 | ABBVIE INC. | $461 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2024 |
| 2024-10-17 | Hoffmann-La Roche Limited | $10,185 | Research payment | Cash or cash equivalent | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | 2024 | |
| 2024-10-17 | E.R. Squibb & Sons, L.L.C. | $2,190 | Research payment | Cash or cash equivalent | ORENCIA Biological, Immunology | An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis | 2024 |
| 2024-10-16 | CSL Behring | $5,622 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-10-16 | JAZZ PHARMACEUTICALS INC. | $2,924 | Research payment | Cash or cash equivalent | EPIDIOLEX Drug, NEUROLOGY | A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannab | 2024 |
| 2024-10-15 | Incyte Corporation | $25,000 | Education | Cash or cash equivalent | 2024 | ||
| 2024-10-09 | ABBVIE INC. | $2,500 | Grant | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | 2024 | |
| 2024-10-08 | PFIZER INC. | $127,859 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | WI211002 PILOT TRIAL OF ANASTROZOLE AND PALBOCICLIB AS FIRSTLINE THERAPY AND AS MAINTENANCE THERAPY AFTER FIRSTLINE CHEM | 2024 |
| 2024-10-07 | Janssen Research & Development, LLC | $34,598 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2024 |
| 2024-10-07 | Janssen Research & Development, LLC | $22,393 | Research payment | Cash or cash equivalent | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-I | 2024 | |
| 2024-10-07 | Janssen Research & Development, LLC | $8,914 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2024 | |
| 2024-10-07 | Janssen Research & Development, LLC | $1,403 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2024 |
| 2024-10-04 | Janssen Research & Development, LLC | $800 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk | 2024 |
| 2024-10-04 | Genmab U.S., Inc. | $518 | Research payment | Cash or cash equivalent | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With | 2024 | |
| 2024-10-03 | Edwards Lifesciences Corporation | $5,475 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2024 | |
| 2024-10-03 | Janssen Research & Development, LLC | $442 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2024 |
| 2024-10-02 | Tanabe Pharma America, Inc. | $27,822 | Research payment | Cash or cash equivalent | A PROSPECTIVE MULTICENTER, LONGITUDINAL, OBSERVATIONAL COHORT STUDY TO ASSESS THE MEASUREMENT PROPERTIES OF CLINICAL OUT | 2024 | |
| 2024-10-01 | Gilead Sciences, Inc. | $143,132 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-10-01 | Gilead Sciences, Inc. | $111,621 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-09-30 | Merck Sharp & Dohme LLC | $418,370 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | STUDY NAME#ToPCourT# A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Locally Advanced Unr | 2024 |
| 2024-09-30 | Janssen Research & Development, LLC | $2,000 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-09-30 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-30 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-30 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-27 | Janssen Research & Development, LLC | $26,057 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-09-26 | Janssen Research & Development, LLC | $3,532 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2024 | |
| 2024-09-25 | Olympus America Inc. | $2,681 | Debt forgiveness | In-kind items and services | EVES EUS ULTRASOUND BRONCHOFIBERVIDEOSCOPE Device, Gastroenterology | 2024 | |
| 2024-09-24 | Gilead Sciences, Inc. | $30,363 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-09-24 | Gilead Sciences, Inc. | $25,273 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-09-23 | E.R. Squibb & Sons, L.L.C. | $51,455 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase I/IIA 2L/3L CRC MSS KRAS Nivo/MEK Combo (trametinib/Novartis) | 2024 |
| 2024-09-23 | Janssen Research & Development, LLC | $3,901 | Research payment | Cash or cash equivalent | A Multi arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2024 | |
| 2024-09-18 | PFIZER INC. | $7,900 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A PHASE 1B DOSE ESCALATION STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND OXALIPLATINBASED CHEMOTHERAPY FOR HER2 | 2024 |
| 2024-09-18 | PFIZER INC. | $796 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A DOSEESCALATION AND DOSEEXPANSION STUDY OF ENFORTUMAB VEDOTIN ASG22CE IN COMBINATION WITH PEMBROLIZUMAB ANDOR CHEMOTHER | 2024 |
| 2024-09-16 | Takeda Pharmaceuticals U.S.A., Inc. | $47,858 | Research payment | Cash or cash equivalent | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2024 | |
| 2024-09-13 | Janssen Research & Development, LLC | $8,914 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2024 | |
| 2024-09-13 | Medical Device Business Services, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VIPER Device, Spine | 2024 | |
| 2024-09-12 | CSL Behring | $35,760 | Research payment | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-09-12 | Edwards Lifesciences Corporation | $13,596 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2024 | |
| 2024-09-10 | Hoffmann-La Roche Limited | $12,773 | Research payment | Cash or cash equivalent | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | 2024 | |
| 2024-09-10 | Hoffmann-La Roche Limited | $10,500 | Research payment | Cash or cash equivalent | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | 2024 | |
| 2024-09-10 | Hoffmann-La Roche Limited | $8,551 | Research payment | Cash or cash equivalent | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | 2024 | |
| 2024-09-10 | Hoffmann-La Roche Limited | $2,560 | Research payment | Cash or cash equivalent | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | 2024 | |
| 2024-09-10 | Hoffmann-La Roche Limited | $1,898 | Research payment | Cash or cash equivalent | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | 2024 | |
| 2024-09-10 | Hoffmann-La Roche Limited | $500 | Research payment | Cash or cash equivalent | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | 2024 | |
| 2024-09-09 | Janssen Research & Development, LLC | $1,265 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3 Study of the Efficacy Safety and Pharmacokinetics of Ustekinumab as Open label Intravenous Induction Treatment | 2024 |
| 2024-09-09 | Janssen Research & Development, LLC | $142 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3 Study of the Efficacy Safety and Pharmacokinetics of Ustekinumab as Open label Intravenous Induction Treatment | 2024 |
| 2024-09-06 | CSL Behring | $74,051 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-09-05 | Janssen Research & Development, LLC | $280 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Openlabel Intravenous Induction Treatment | 2024 |
| 2024-09-04 | Tanabe Pharma America, Inc. | $44,470 | Research payment | Cash or cash equivalent | A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF MT-3921 IN SUBJECTS | 2024 | |
| 2024-09-02 | Insmed, Inc. | $2,000 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-02 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-02 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-02 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-02 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-02 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-02 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-02 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-08-30 | Janssen Research & Development, LLC | $810 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide a | 2024 |
| 2024-08-29 | Takeda Pharmaceuticals U.S.A., Inc. | $170,608 | Research payment | Cash or cash equivalent | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2024 | |
| 2024-08-29 | Janssen Research & Development, LLC | $19,143 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2024 |
| 2024-08-26 | Janssen Research & Development, LLC | $2,500 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-08-23 | Merck Sharp & Dohme LLC | $4,709 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2024 |
| 2024-08-22 | Janssen Research & Development, LLC | $1,511 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3 Study of the Efficacy Safety and Pharmacokinetics of Ustekinumab as Open label Intravenous Induction Treatment | 2024 |
| 2024-08-22 | Janssen Research & Development, LLC | $1,064 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2024 | |
| 2024-08-22 | Janssen Research & Development, LLC | $121 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2024 | |
| 2024-08-15 | Janssen Research & Development, LLC | $36,974 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-08-15 | CSL Behring | $35,760 | Research payment | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-08-15 | Takeda Pharmaceuticals U.S.A., Inc. | $7,318 | Research payment | Cash or cash equivalent | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2024 | |
| 2024-08-15 | Takeda Pharmaceuticals U.S.A., Inc. | $6,680 | Research payment | Cash or cash equivalent | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2024 | |
| 2024-08-15 | Takeda Pharmaceuticals U.S.A., Inc. | $3,892 | Research payment | Cash or cash equivalent | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2024 | |
| 2024-08-14 | PFIZER INC. | $159,823 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | WI211002 PILOT TRIAL OF ANASTROZOLE AND PALBOCICLIB AS FIRSTLINE THERAPY AND AS MAINTENANCE THERAPY AFTER FIRSTLINE CHEM | 2024 |
| 2024-08-12 | Janssen Research & Development, LLC | $6,670 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2024 | |
| 2024-08-09 | ABBVIE INC. | $58,502 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | 2024 |
| 2024-08-09 | Amgen Inc. | $11,000 | Research payment | Cash or cash equivalent | P2b SLE | 2024 | |
| 2024-08-08 | PFIZER INC. | $159,823 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | WI211002 PILOT TRIAL OF ANASTROZOLE AND PALBOCICLIB AS FIRSTLINE THERAPY AND AS MAINTENANCE THERAPY AFTER FIRSTLINE CHEM | 2024 |
| 2024-08-07 | CSL Behring | $72,931 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-08-06 | Gilead Sciences, Inc. | $2,800 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2024 |
| 2024-08-02 | Janssen Research & Development, LLC | $5,965 | Research payment | Cash or cash equivalent | A Multi arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2024 | |
| 2024-08-01 | PFIZER INC. | $25,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-08-01 | Edwards Lifesciences Corporation | $13,179 | Research payment | Cash or cash equivalent | TRISCEND II Pivotal (2020-05) | 2024 | |
| 2024-07-31 | GLOBAL BLOOD THERAPEUTICS, INC. | $8,354 | Research payment | Cash or cash equivalent | OXBRYTA Drug, HEMATOLOGY | AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXEL | 2024 |
| 2024-07-29 | Janssen Research & Development, LLC | $11,878 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2024 |
| 2024-07-29 | Janssen Research & Development, LLC | $932 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk | 2024 |
| 2024-07-26 | Janssen Research & Development, LLC | $4,752 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-07-26 | Janssen Research & Development, LLC | $1,775 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3 Study of the Efficacy Safety and Pharmacokinetics of Ustekinumab as Open label Intravenous Induction Treatment | 2024 |
| 2024-07-26 | Insmed, Inc. | $50 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-07-26 | Insmed, Inc. | $50 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-07-26 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-07-26 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-07-26 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-07-26 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-07-26 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-07-26 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-07-26 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-07-26 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-07-26 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-07-26 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-07-26 | Insmed, Inc. | $25 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-07-25 | Janssen Research & Development, LLC | $3,669 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2024 | |
| 2024-07-25 | Janssen Research & Development, LLC | $532 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2024 | |
| 2024-07-24 | PFIZER INC. | $2,587 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A DOSEESCALATION AND DOSEEXPANSION STUDY OF ENFORTUMAB VEDOTIN ASG22CE IN COMBINATION WITH PEMBROLIZUMAB ANDOR CHEMOTHER | 2024 |
| 2024-07-24 | Genmab A/S | $200 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2024 |
| 2024-07-23 | JAZZ PHARMACEUTICALS INC. | $6,172 | Research payment | Cash or cash equivalent | EPIDIOLEX Drug, NEUROLOGY | A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannab | 2024 |
| 2024-07-18 | Silk Road Medical, Inc. | $10,910 | Research payment | Cash or cash equivalent | ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter Device, Cardiology/Vascular Diseases | Roadster 3 | 2024 |
| 2024-07-17 | CSL Behring | $5,379 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-07-15 | E.R. Squibb & Sons, L.L.C. | $2,276 | Research payment | Cash or cash equivalent | OPDUALAG Drug, Oncology | Ph II/III IO Naive Mel (lag3 + nivo FDC) - A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolu | 2024 |
| 2024-07-11 | Janssen Research & Development, LLC | $24,560 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2024 | |
| 2024-07-08 | Janssen Research & Development, LLC | $12,144 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2024 |
| 2024-07-05 | Intercept Pharma Europe Ltd. | $48,741 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2024 |
| 2024-07-01 | JAZZ PHARMACEUTICALS INC. | $9,853 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | EMERGE-201: A Phase 2, Multicenter, Open-label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced | 2024 |
| 2024-07-01 | Janssen Research & Development, LLC | $4,000 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-07-01 | Genmab A/S | $200 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2024 |
| 2024-06-27 | Artivion, Inc. | $8,405 | Research payment | Cash or cash equivalent | AMDS-Ascyrus Medical Device, Cardiovascular and vascular surgery | PERSEVERE | 2024 |
| 2024-06-26 | Medical Device Business Services, Inc. | $26,567 | Royalty or License | Cash or cash equivalent | NA Device, Trauma | 2024 | |
| 2024-06-26 | Intercept Pharma Europe Ltd. | $3,000 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2024 |
| 2024-06-24 | Janssen Research & Development, LLC | $24,876 | Research payment | Cash or cash equivalent | A Multi arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2024 | |
| 2024-06-24 | Janssen Research & Development, LLC | $7,500 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3 Study of the Efficacy Safety and Pharmacokinetics of Ustekinumab as Open label Intravenous Induction Treatment | 2024 |
| 2024-06-24 | Edwards Lifesciences Corporation | $750 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2024 | |
| 2024-06-20 | PFIZER INC. | $6,840 | Research payment | Cash or cash equivalent | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHER | 2024 | |
| 2024-06-20 | Janssen Research & Development, LLC | $3,653 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2024 | |
| 2024-06-19 | Bolton Medical Inc | $1,780 | Research payment | Cash or cash equivalent | RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Device, ENDOVASCULAR AORTIC REPAIR | RELAYPRO-T | 2024 |
| 2024-06-14 | Janssen Research & Development, LLC | $5,840 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2024 |
The latest 200 records of 467.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Monroe, NC, county Union County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Monroe, NC | County Union County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 36,759 | 250,958 | 10,730,404 |
| Population, 2020 census P1 | 34,562 | 238,267 | 10,439,388 |
| Median age B01002 | 35.5 | 39.2 | 39.1 |
| Under 18 B01001 | 24.5% | 25.6% | 21.8% |
| 65 and over B01001 | 14.9% | 13.5% | 17.2% |
| Households B11001 | 12,620 | 84,237 | 4,282,345 |
| Foreign born B05002 | 17.8% | 12.2% | 9.1% |
| Median household income B19013 | $72,540 | $102,900 | $72,388 |
| Median family income B19113 | $80,817 | $118,218 | $90,290 |
| Per capita income B19301 | $31,089 | $46,949 | $41,385 |
| Poverty rate B17001 | 13.3% | 7.7% | 13.0% |
| Unemployment rate B23025 | 4.6% | 4.2% | 4.7% |
| Civilian labor force B23025 | 18,613 | 132,592 | 5,336,863 |
| Mean commute (minutes) B08013 | 30.1 | 29.8 | 25.1 |
| Bachelor's degree or higher B15003 | 24.1% | 40.5% | 35.7% |
| Housing units B25001 | 13,469 | 88,851 | 4,895,668 |
| Owner-occupied B25003 | 61.6% | 81.6% | 66.6% |
| Renters B25003 | 38.4% | 18.4% | 33.4% |
| Median home value B25077 | $309,100 | $417,300 | $288,900 |
| Median gross rent B25064 | $1,246 | $1,496 | $1,228 |
| White, not Hispanic B03002 | 43.7% | 66.8% | 60.0% |
| Black B03002 | 19.7% | 10.9% | 20.0% |
| Hispanic or Latino B03002 | 30.9% | 13.4% | 11.3% |
| Asian B03002 | 1.0% | 4.5% | 3.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Monroe, NC.
Comments